Tenderwize
Zurück zur Suche

Open House Drug Rebate Agreements Lamotrigine, ATC N03AX09

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 05, 2027 · 220 days left·Open·Supplies·Framework
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lamotrigin, ATC N03AX09

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

20 / 100

Risikofaktoren

Open-house model provides no exclusivity; other buyers may have separate contracts. This may limit demand.

Administrative burden of paper submission (two originals) or requiring qualified electronic signature.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Supply of pharmaceutical products containing Lamotrigine (ATC N03AX09)
  • Non-exclusive rebate agreement under §130a Abs. 8 SGB V
Vollständige Zusammenfassung anzeigen

Open-house model for non-exclusive drug rebate agreements for Lamotrigine (ATC N03AX09) with AOK Bayern. All eligible pharmaceutical companies can join. No competitive selection; contracts are identical and non-negotiable. Duration: 01.06.2025 to 31.05.2027. Applications accepted until 05.04.2027. No estimated value published.

Risiken

Open-house model provides no exclusivity; other buyers may have separate contracts. This may limit demand.

Administrative burden of paper submission (two originals) or requiring qualified electronic signature.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel' required.

Eligibility

  • Only pharmaceutical companies are eligible.

Administrative

  • Must submit signed self-declaration of reliability.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open House Drug Rebate Agreements Lamotrigine, ATC N03AX09

Non-exclusive rebate agreements for the active substance Lamotrigine. All interested pharmaceutical companies meeting eligibility criteria may sign identical contracts. The contract start is flexible (earliest 01.06.2025) and ends 31.05.2027.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

May 2025 - May 2027

Kategorie

Pharmaceutical products

Frist

Deadline Apr 05, 2027

Vergabedetails

Veröffentlichungsdatum
15 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
247124-2025

Dokumente (2)

Ähnliche Ausschreibungen